Determination of Urinary Calcium and Citrate Ratios in Children With Urolithiasis
The European Research Journal · 2026-11-01 · 1286-1292
DOI: 10.18621/eurj.1252 ↗Abstract
Objective: The random urinary calcium-to-creatinine (UCa/Cr) ratio varies significantly with age, requiring age-specific reference ranges for accurate interpretation. This study aimed to compare the random urinary calcium-to-citrate (UCa/Cit) ratio between children with urolithiasis and a healthy control group, examine its relationship with age and sex, and evaluate its performance in differentiating children with urolithiasis from healthy controls. Methods: This case-control study included 121 children aged 1 to 18 years with urolithiasis and 107 age- and sex-matched healthy controls. UCa/Cr and UCa/Cit ratios were calculated from spot urine samples. Differences between the groups were compared, age- and sex-related trends were evaluated, and receiver operating characteristic (ROC) curve analysis was performed to determine diagnostic performance. Results: The UCa/Cit level was significantly higher in the patient group compared with the control group (mean [SD], 1.28 [2.87] vs 0.63 [1.51] mg/mg; P < .001). The UCa/Cit ratio did not show a statistically significant association with age or sex in this cohort. In the ROC curve analysis, a value of 0.390 mg/mg was determined as the optimal cutoff point for the UCa/Cit ratio to distinguish children with urolithiasis from healthy controls, yielding a sensitivity of 66.3%, a specificity of 65.2%, and an area under the curve of 0.675 (95% CI, 0.605-0.745; P < .001). Conclusions: Although the UCa/Cit ratio was significantly elevated in children with urolithiasis and was independent of age or sex in this cohort, its standalone discriminatory performance remained limited. Therefore, the UCa/Cit ratio should be considered a supportive metabolic parameter rather than a standalone diagnostic or screening test. Additional multicenter studies with standardized dietary assessment and repeated sampling are required to validate its clinical use.
EUVIMED